Dorzolamide — Membership Pricing

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Glaucoma

• Brimonidine
• Latanoprost
• Timolol

Other medications in Ophthalmology

• Faricimab
• Fluorescein
• Latanoprostene Bunod
• Lifitegrast
• Methazolamide
• Netarsudil
• Pegaptanib
• Phenylephrine Eye

About Dorzolamide

Dorzolamide is a crucial medication often prescribed to manage eye conditions like glaucoma and ocular hypertension by reducing elevated eye pressure. For many, the cost can be a barrier. Dorzolamide, often prescribed as an ophthalmic solution, plays a vital role in the management of elevated intraocular pressure (IOP). This condition, if left untreated, can lead to serious eye diseases such as open-angle glaucoma and ocular hypertension, potentially causing irreversible vision loss. By effectively lowering eye pressure, dorzolamide helps protect your optic nerve and preserve your sight.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Dorzolamide is approved for (FDA label)

Dorzolamide hydrochloride ophthalmic solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Dorzolamide hydrochloride ophthalmic solution is a carbonic anhydrase inhibitor indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. (1)

Source: Read the full FDA label on DailyMed. Label effective date: October 4, 2024.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Dorzolamide (FDA label)

Ophthalmic solution containing dorzolamide 2% (20 mg/mL) equivalent to 22.3 mg/mL of dorzolamide hydrochloride. Ophthalmic solution containing dorzolamide 2% (20 mg/mL). (3)

Source: FDA prescribing information (DailyMed). Set ID: 462a61b2-1ec6-4d18-bc6b-fc03e027caa0. SPL document ID: 746e0cc7-7ea7-4090-acb3-69de5fe85be3. Label effective date: October 4, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Dorzolamide (FDA label)

The most frequently reported adverse reactions associated with dorzolamide hydrochloride ophthalmic solution were ocular burning, stinging, or discomfort immediately following ocular administration (approximately one-third of patients). Approximately one-quarter of patients noted a bitter taste following administration.

Source: FDA prescribing information (DailyMed). Set ID: 462a61b2-1ec6-4d18-bc6b-fc03e027caa0. SPL document ID: 746e0cc7-7ea7-4090-acb3-69de5fe85be3. Label effective date: October 4, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Dorzolamide (FDA label)

Dorzolamide hydrochloride ophthalmic solution is contraindicated in patients who are hypersensitive to any component of this product [see Warnings and Precautions ( 5.1 )]. Dorzolamide hydrochloride ophthalmic solution is contraindicated in patients who are hypersensitive to any component of this product. (4, 5.1)

Source: FDA prescribing information (DailyMed). Set ID: 462a61b2-1ec6-4d18-bc6b-fc03e027caa0. SPL document ID: 746e0cc7-7ea7-4090-acb3-69de5fe85be3. Label effective date: October 4, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Dorzolamide (FDA label)

• Sulfonamide Hypersensitivity (5.1) • Bacterial Keratitis (5.2) • Corneal Endothelium (5.3) • Allergic Reactions (5.4) • Acute Angle-Closure Glaucoma (5.5) 5.1 Sulfonamide Hypersensitivity Dorzolamide hydrochloride ophthalmic solution contains dorzolamide, a sulfonamide; and although administered topically, it is absorbed systemically. Therefore, the same types of adverse reactions that are attributable to sulfonamides may occur with topical administration of dorzolamide hydrochloride ophthalmic solution. Fatalities have occurred, although rarely, due to severe reactions to sulfonamides including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias. Sensitization may recur when a sulfonamide is readministered irrespective of the route of administration. If signs of serious reactions or hypersensitivity occur, discontinue the use of this preparation [see Contraindications ( 4 )] . 5.2 Bacterial Keratitis There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products.

Source: FDA prescribing information (DailyMed). Set ID: 462a61b2-1ec6-4d18-bc6b-fc03e027caa0. SPL document ID: 746e0cc7-7ea7-4090-acb3-69de5fe85be3. Label effective date: October 4, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Dorzolamide (FDA label)

· Potential additive effect of oral carbonic anhydrase inhibitor with dorzolamide hydrochloride ophthalmic solution . (7.1) Potential acid-base and electrolyte disturbances. (7.2) 7.1 Oral Carbonic Anhydrase Inhibitors There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral carbonic anhydrase inhibitor and dorzolamide hydrochloride ophthalmic solution. The concomitant administration of dorzolamide hydrochloride ophthalmic solution and oral carbonic anhydrase inhibitors is not recommended. 7.2 High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). Therefore, the potential for such drug interactions should be considered in patients receiving dorzolamide hydrochloride ophthalmic solution.

Source: FDA prescribing information (DailyMed). Set ID: 462a61b2-1ec6-4d18-bc6b-fc03e027caa0. SPL document ID: 746e0cc7-7ea7-4090-acb3-69de5fe85be3. Label effective date: October 4, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.